Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Does evidence support supervised injection sites?

Jennifer Ng, Christy Sutherland and Michael R. Kolber
Canadian Family Physician November 2017, 63 (11) 866;
Jennifer Ng
Medical student in the Faculty of Medicine and Dentistry at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christy Sutherland
Medical Director of the Portland Hotel Society in Vancouver, BC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Kolber
Associate Professor in the Department of Family Medicine at the University of Alberta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Do supervised injection sites (SISs) reduce mortality, hospitalizations, ambulance calls, or disease transmission?

Bottom line

Best evidence from cohort and modeling studies suggests that SISs are associated with lower overdose mortality (88 fewer overdose deaths per 100 000 person-years [PYs]), 67% fewer ambulance calls for treating overdoses, and a decrease in HIV infections. Effects on hospitalizations are unknown.

Evidence

  • One high-quality cohort study examined overdose mortality before and after an SIS opened in Vancouver, BC.1

    • -Of persons living within 500 m of the SIS (70% of SIS users), overdose deaths decreased from 253 to 165 per 100 000 PYs and the absolute risk difference was 88 deaths per 100 000 PYs; 1 overdose death was prevented annually for every 1137 users.

    • -There was no change in mortality in the rest of city.

  • Before the SIS opened, 35% of 598 intravenous drug users were admitted to hospital in a 3-year period,2 15% for skin infections.

    • -After the SIS opened, of 1083 SIS users over 4 years,3 9% were admitted with cutaneous injection-related infections (including osteomyelitis and endocarditis).

    • -While SIS nurse “referral” to hospital increased the likelihood of admission, the average length of stay decreased by 8 days (from 12 to 4).3

    • -Indirect comparison of different cohorts is a limitation.

  • Near one SIS, average monthly ambulance calls with naloxone treatment for suspected opioid overdose decreased from 27 to 9 (relative risk reduction of 67%).4

  • About 6 to 57 HIV infections per year are prevented by the SIS according to mathematical modeling.5,6

    • -Limitations include assumptions made about drug use and injecting practices, and might include benefit from needle exchange programs.6

Context

  • The age-standardized mortality rate among intravenous drug users is about 8 times higher than in the rest of the population.7

  • The benefit of the SIS is likely limited by site capacity: the SIS assists only about 4% of all injections in Vancouver’s Downtown Eastside.5

  • Educating SIS users likely contributes to decreased syringe borrowing (37% in 1996 to 2% in 2011).7

  • There is about 1 overdose at the SIS per 1000 injections; no fatal overdoses have been reported.8

  • All studies show health care savings for each $1 spent.6,9

  • Opening the SIS did not increase arrests for drug trafficking, assaults, or robberies.10

Implementation

There are more than 90 SISs worldwide11; Vancouver’s SIS has operated since 2003. Many other Canadian jurisdictions are planning SISs; these should be tailored to community needs. Services at SISs include emergency response to overdoses; injection-related first aid; assessment and referral to primary health care; harm reduction counseling; exchange of needles and other drug paraphernalia; and condom provision.12 These sites support users to seek counseling, detoxification, and treatment for addiction.12 Details about operating an SIS can be found online.11

Notes

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • Competing interests

    Dr Sutherland is Medical Director of the Portland Hotel Society, the non-profit that runs Vancouver’s safe injection site (InSite) in partnership with the Vancouver Coastal Health Authority. The other authors have no potential conflicts of interest.

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Marshall BD,
    2. Milloy MJ,
    3. Wood E,
    4. Montaner JSG,
    5. Kerr T
    . Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011;377(9775):1429-37.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Palepu A,
    2. Tyndall MW,
    3. Leon H,
    4. Muller J,
    5. O’Shaughnessy MV,
    6. Schechter MT,
    7. et al
    . Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001;165(4):415-20.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Lloyd-Smith E,
    2. Wood E,
    3. Zhang R,
    4. Tyndall MW,
    5. Sheps S,
    6. Montaner JSG,
    7. et al
    . Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health 2010;10:327.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Salmon AM,
    2. van Beek I,
    3. Amin J,
    4. Kaldor J,
    5. Maher L
    . The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction 2010;105(4):676-83.
    OpenUrlPubMed
  5. 5.↵
    1. Pinkerton SD
    . How many HIV infections are prevented by Vancouver Canada’s supervised injection facility? Int J Drug Policy 2011;22(3):179-83.
    OpenUrlPubMed
  6. 6.↵
    1. Andresen MA,
    2. Boyd N
    . A cost-benefit and cost-effectiveness analysis of Vancouver’s supervised injection facility. Int J Drug Policy 2010;21(1):70-6.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Urban Health Research Initiative
    . Drug situation in Vancouver. 2nd ed. Vancouver, BC: British Columbia Centre for Excellence in HIV/AIDS; 2013.
  8. 8.↵
    1. Kerr T,
    2. Tyndall MW,
    3. Lai C,
    4. Montaner JSG,
    5. Wood E
    . Drug-related overdoses within a medically supervised safer injection facility. Int J Drug Policy 2006;17(5):436-41.
    OpenUrlCrossRef
  9. 9.↵
    1. Pinkerton SD
    . Is Vancouver Canada’s supervised injection facility cost-saving? Addiction 2010;105(8):1429-36.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Wood E,
    2. Tyndall MW,
    3. Lai C,
    4. Montaner JSG,
    5. Kerr T
    . Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy 2006;1:13.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. British Columbia Centre on Substance Use
    . Supervised consumption services. Vancouver, BC: British Columbia Ministry of Health; 2017. Available from: www.bccsu.ca/wp-content/uploads/2017/07/BC-SCS-Operational-Guidance.pdf. Accessed 2017 Sep 1.
  12. 12.↵
    1. Health Canada
    . Vancouver’s INSITE service and other supervised injection sites: what has been learned from research? Ottawa, ON: Health Canada; 2008. Available from: www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications/vancouver-insite-service-other-supervised-injection-sites-what-been-learned-research.html. Accessed 2017 Sep 3.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 63 (11)
Canadian Family Physician
Vol. 63, Issue 11
1 Nov 2017
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does evidence support supervised injection sites?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Does evidence support supervised injection sites?
Jennifer Ng, Christy Sutherland, Michael R. Kolber
Canadian Family Physician Nov 2017, 63 (11) 866;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Does evidence support supervised injection sites?
Jennifer Ng, Christy Sutherland, Michael R. Kolber
Canadian Family Physician Nov 2017, 63 (11) 866;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Tools for Practice

  • Topical treatments for anal fissure
  • Antibiotic prophylaxis for urinary tract infection
  • Pediatric diarrhea and lactose products
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire